Megakaryocyte Heterogeneity in Sickle Cell Disease

Not yet recruiting

• Conditions: Sickle Cell Disease (SCD)

• Registration Number: NCT06850337
• Lead Sponsor: Centre Hospitalier Universitaire de la Guadeloupe

Brief Summary

Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crisis called vaso-occlusive crisis (VOC) and chronic inflammation. Activated platelets of SCD patients participated to both chronic inflammation and painful VOC. Platelets are anucleated cells from the fragmentation of megakaryocytes in bone marrow.

The main aim of this study is to characterize the distribution of the different megakaryocyte subpopulations of sickle cell disease patients SS and SC and in particular the "immune" megakaryocytes CD148+CD48+ and to compare it with the platelet phenotype.

Detailed Description

Platelets are activated in all sickle cell disease patients at baseline with higher expression of selective P (CD62P). Platelets provide a major function in primary hemostasis by the formation of the platelet clot and also participate in coagulation through the formation of an electro-negative phospholipid surface essential to the enzymes of the coagulation cascade. It is now known that platelets are also immune cells that are able to secrete pro-inflammatory cytokines (TGF beta, IFN gamma), that they express certain Toll-like receptors (TLR4) and the inflammasome NLRP3 leading to the activation of caspase-1. Several teams, including ours, have shown that inflammasome and/or caspase-1 can be activated in an infectious context, particularly viral (dengue fever, COVID) and inflammatory (chronic inflammatory bowel diseases, etc.).

Platelets are anucleated cells from the fragmentation of megakaryocytes. Their protein profile is therefore the result of bone marrow differentiation of megakaryocytes. Recently, it has been shown a cellular heterogeneity within megakaryocytes including immune megakaryocytes whose proportion can significantly increase in stress and inflammation condition. It is not clear whether these immune megakaryocytes that could behave as antigen-presenting cells are capable of producing blood platelets.

We wonder whether sickle cell disease patients have a different proportion of these immune megakaryocytes compared to healthy subjects and whether their activated blood platelets carry specific markers of these immune megakaryocytes.

SCD patients will be recruited in the active file of the sickle cell center of Guadeloupe. Two groups of patients will be constituted: SS patients and SC patients. The control group will be composed of patients who come for hip or knee replacement and do not suffer from chronic disease. Only one blood and bone marrow collection will be realized during the study.

Study Timeline

• Study First Submitted: 2025-02-24
• Study First Submitted QC: 2025-02-24
• Study First Posted: 2025-02-27
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-23
• Last Update Posted: 2025-05-25
• Study Start: 2025-07
• Primary Completion: 2027-03
• Study Completion: 2027-03

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• patients with SS or SC SCD
• diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies
• patients older than 18 years at inclusion
• clinically in a steady state at inclusion (without complication in the last month and without transfusion in the three last months)
• patient followed up for SCD at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe à Pitre)
• patients who will provide written informed consent in accordance with the Declaration of Helsinki
• patients affiliated to national social security
• the control group (AA subjects) will be patients older than 18 years old who come at the University hospital of Guadeloupe, (Pointe à Pitre) for hip or knee replacement and will do not suffer from chronic disease.

Exclusion Criteria

• patients younger than 18 years old
• patients with hemoglobinopathy other than SS and SC SCD
• patients with a transfusion therapy or on bleeding therapy for less than three months
• patients no affiliated to national social security
• pregnant or breastfeeding patients

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
proportion of immune megakaryocytes CD148+CD48+ in bone marrow	24 months	The primary outcome will be the evaluation of the proportion of immune megakaryocytes CD148+CD48+ in bone marrow of sickle cell disease patients in comparison to control group.

Secondary Outcome Measures

Name	Time	Method
platelet phenotype	24 months	The secondary outcomes are to compare the platelet phenotype between the three groups of patients, including the proportion of CD148+CD48+ platelets, to study the activation of this platelet subpopulation (expression of CD62P) and establish whether there is a relationship between the proportion of immune megakaryocytes in the bone marrow and the proportion of CD148+CD48+ platelets in the blood.

Trial Locations

Locations (1)

Chu de La Guadeloupe; 🇬🇵 Pointe-à-Pitre, Guadeloupe